Home » Aaron Kantor, Frank Torti

Aaron Kantor, Frank Torti

Apr 10, 2008
Premium
The Immune Tolerance Institute this week said Aaron Kantor joined the company as chief scientific officer.
 
Prior to ITI, Kantor was executive director of cell and molecular biology for biomarker discovery sciences at Pharmaceutical Product Development, a contract research organization. Before that, he was manager for the rare cell program and cell depletion therapeutic program at AmCell.
 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

What's Popular?

In Proteomics & Protein Research

  1. Pan-Cancer Mutation Study Identifies Protein Kinases Key to Tumor Suppression

    Premium

  2. Top Down Proteomics Identifies Protein-Level Effects of KRAS Mutations in Colorectal Cancer

    Premium

  3. Advances in Mass Spec Push Single-Cell Proteomics Toward Feasibility

    Premium

  4. IsoPlexis Uses Single-Cell Platform to Assess T Cell Activity in CAR-T Cancer Therapy

    Premium

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.